Huntington’s disease is a rare genetic disorder affecting movement, memory, and mood. Here’s what we know—and what’s ahead.

It was found that those with severe hemophilia B have less than 1% of normal factor IX activity, often experiencing spontaneous bleeding that can cause joint damage or life-threatening events.

Gene therapy has proved to be a safe long-term treatment for haemophilia B. The benefits of a single dose persist for at ...

A new hereditary condition has been discovered that affects patients' ability to repair DNA—leaving them both at greater risk ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Learn how clotting factor therapy, gene therapy, and non-factor treatments are improving hemophilia prognosis and life expectancy.

A gene transfer approach to treating the bleeding disorder hemophilia B remains safe and effective long-term, as scientists ...

In a 13-year follow-up by St. Jude Children’s Research Hospital and University College London published in The New England ...

A gene transfer approach to treating the bleeding disorder hemophilia B remains safe and effective long-term, as scientists from St. Jude Children's ...

Hemophilia A Market Trends The report provides a detailed analysis of the current hemophilia A marketed drugs and late-stage pipeline drugs ...